Basit öğe kaydını göster

dc.contributor.authorLoeffen, Jan L. C.
dc.contributor.authorPillon, Marta
dc.contributor.authorAnderzhanova, Liliya
dc.contributor.authorKabíčková, Edita
dc.contributor.authorChiang, Alan K. S.
dc.contributor.authorMellgren, Karin
dc.contributor.authorLazic, Jelena
dc.contributor.authorJazbec, Janez
dc.contributor.authorMeijerink, Jules P. P.
dc.contributor.authorBeishuizen, Auke
dc.contributor.authorKebudi, Rejin
dc.contributor.authorKroeze, Emma
dc.contributor.authorArias Padilla, Laura
dc.contributor.authorBakker, Max
dc.contributor.authorBoer, Judith M.
dc.contributor.authorHagleitner, Melanie M.
dc.contributor.authorBurkhardt, Birgit
dc.contributor.authorMori, Takeshi
dc.contributor.authorAttarbaschi, Andishe
dc.contributor.authorVerdú-Amorós, Jaime
dc.date.accessioned2023-02-21T08:51:24Z
dc.date.available2023-02-21T08:51:24Z
dc.date.issued2022
dc.identifier.citationKroeze E., Arias Padilla L., Bakker M., Boer J. M., Hagleitner M. M., Burkhardt B., Mori T., Attarbaschi A., Verdú-Amorós J., Pillon M., et al., "Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement", Cancers, cilt.14, sa.16, 2022
dc.identifier.issn2072-6694
dc.identifier.othervv_1032021
dc.identifier.otherav_234db765-35b9-49f2-988d-23757f8ece22
dc.identifier.urihttp://hdl.handle.net/20.500.12627/187025
dc.identifier.urihttps://doi.org/10.3390/cancers14163895
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/234db765-35b9-49f2-988d-23757f8ece22/file
dc.description.abstract© 2022 by the authors.B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1–18 years (p = 0.0080), and that the outcome for infants (0–1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectYaşam Bilimleri
dc.subjectSitogenetik
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectKanser Araştırmaları
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.titlePediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement
dc.typeMakale
dc.relation.journalCancers
dc.contributor.departmentİstanbul Üniversitesi , Onkoloji Enstitüsü , Klinik Onkoloji Ana Bilim Dalı
dc.identifier.volume14
dc.identifier.issue16
dc.contributor.firstauthorID4113532


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster